Cure My Disease

Don't miss your cure!

 Log in / Sign up

Obesity drug may ignite 'Brown Fat' to torch calories

NCT ID NCT06893211

Completed Disease control Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests whether the weight-loss drug tirzepatide can increase the activity of brown and beige fat—special fat cells that burn energy instead of storing it. The trial includes women with obesity who will receive either tirzepatide or a placebo for 24 weeks. Researchers will use imaging and fat tissue samples to measure changes in brown fat activity and related health markers like weight, metabolism, and blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tirzepatide
What this could lead to
If tirzepatide activates brown fat, it could point toward a new way to treat obesity by increasing calorie burning, not just reducing appetite.
What could go wrong
This is a small, early-phase study in women only, so results may not apply to everyone. The drug may not activate brown fat as hoped, and side effects like nausea or digestive issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

  • Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana

    Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.